Opinion|Videos|December 14, 2023
KRYSTAL-1: Follow-Up Data on Adagrasib Monotherapy in Patients with Advanced/Metastatic KRASG12C Mutated NSCLC
Author(s)Narjust Florez, MD
Dr Narjust Florez discusses the KRYSTAL-1 trial, focusing on the effectiveness and side effects of adagrasib in treating patients with NSCLC and KRASG12C mutations, and noting their impact on progression-free and overall survival.
Advertisement
Episodes in this series
Advertisement
Related to this article
Dan Costin, MD, discusses where personalized mRNA vaccines could fit into lung cancer care within 5 to 10 years.
Dan Costin, MD, describes counseling his first patient on a personalized mRNA vaccine vs observation in the INTerpath-014 trial.
The phase 3 FURVENT trial showed an objective response rate benefit with firmonertinib in EGFR exon 20 insertion–mutant NSCLC.
Dan Costin, MD, explains the rationale for testing a personalized mRNA vaccine after resection of high-risk stage I NSCLC.
Data from the REZILIENT3 trial support the NDA for zipalertinib plus chemotherapy for those with NSCLC harboring EGFR exon 20 insertion mutations.
Xiuning Le, MD, PhD, discusses the accelerated approval of frontline sevabertinib for patients with HER2-mutated non–small cell lung cancer.
Clinicians must think a lot about how to make testing and novel treatment advances available for patients globally, according to Chul Kim, MD, MPH.
Advertisement
Advertisement
Trending on CancerNetwork
1
Selinexor-Based Quadruplet Targets Myeloma After T-Cell Redirecting Therapy
2
Taking The First Steps for a Personalized Lung Cancer Vaccine Trial
3
Firmonertinib Misses PFS End Point in First-Line EGFR Exon 20 NSCLC
4
Rinatabart Sesutecan Elicits Responses in PROC Regardless of FRα Expression
5